![PDF) Uncertain Diagnosis of Fabry Disease in Patients with Neuropathic Pain, Angiokeratoma or Cornea Verticillata: Consensus on the Approach to Diagnosis and Follow-Up PDF) Uncertain Diagnosis of Fabry Disease in Patients with Neuropathic Pain, Angiokeratoma or Cornea Verticillata: Consensus on the Approach to Diagnosis and Follow-Up](https://i1.rgstatic.net/publication/265690955_Uncertain_Diagnosis_of_Fabry_Disease_in_Patients_with_Neuropathic_Pain_Angiokeratoma_or_Cornea_Verticillata_Consensus_on_the_Approach_to_Diagnosis_and_Follow-Up/links/54267a8d0cf238c6ea779457/largepreview.png)
PDF) Uncertain Diagnosis of Fabry Disease in Patients with Neuropathic Pain, Angiokeratoma or Cornea Verticillata: Consensus on the Approach to Diagnosis and Follow-Up
![PDF) Reference values for lysosomal enzymes activities using dried blood spots samples—A Brazilian experience PDF) Reference values for lysosomal enzymes activities using dried blood spots samples—A Brazilian experience](https://i1.rgstatic.net/publication/47335477_Reference_values_for_lysosomal_enzymes_activities_using_dried_blood_spots_samples-A_Brazilian_experience/links/02e7e51ad3715e917b000000/largepreview.png)
PDF) Reference values for lysosomal enzymes activities using dried blood spots samples—A Brazilian experience
![Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1 ... Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1 ...](https://ars.els-cdn.com/content/image/1-s2.0-S0960896617314633-gr3.jpg)
Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1 ...
![2015 ESC guidelines for the management of patients with ventricular arrhythmias and preventionof sudden cardiac death | PDF 2015 ESC guidelines for the management of patients with ventricular arrhythmias and preventionof sudden cardiac death | PDF](https://image.slidesharecdn.com/2015escguidelinesforthemanagementofpatientswithventriculararrhythmiasandpreventionofsuddencardiacdea-151218081655/85/2015-esc-guidelines-for-the-management-of-patients-with-ventricular-arrhythmias-and-preventionof-sudden-cardiac-death-2-320.jpg?cb=1668040053)
2015 ESC guidelines for the management of patients with ventricular arrhythmias and preventionof sudden cardiac death | PDF
![Assessment of the 12-Lead ECG as a Screening Test for Detection of Cardiovascular Disease in Healthy General Populations of Young People (12–25 Years of Age) | Circulation Assessment of the 12-Lead ECG as a Screening Test for Detection of Cardiovascular Disease in Healthy General Populations of Young People (12–25 Years of Age) | Circulation](https://www.ahajournals.org/cms/asset/2d417cfb-3b7a-4601-b10d-deb12c888c79/1303fig01.jpeg)